We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App





Meridian Bioscience Launches New Animal-Free Immunoassay Interference Blockers

By LabMedica International staff writers
Posted on 26 Jul 2023

Meridian Bioscience Inc. More...

(Cincinnati, OH, USA) is spotlighting its newly-introduced animal-free immunoassay interference blockers at this year's AACC conference. Immunoassay interference can lead to false positives and negatives, resulting in incorrect interpretation and faulty patient diagnosis. Interference primarily stems from Human Anti-Mouse Antibodies (HAMA), Rheumatoid Factor (RF), and Heterophilic Antibodies (HA). HAMA, detected in up to 25% of patients, combined with HA, constitute the major factors contributing to false positives in immunoassays. Including blockers in every immunoassay is essential to avoid such interference. Traditionally, animal-based interference blockers have been employed to enhance assay accuracy; however, these are prone to cross-reactivity with assay reagents, lot-to-lot variability, and supply shortages, as evidenced during the COVID-19 pandemic.

Meridian's Life Science division has unveiled two new animal-free immunoassay interference blockers, K-Block, and Mouse-Free IgG, offering a potential solution to these issues. These innovative blockers are completely animal-free and provide comparable or superior performance than traditional animal-derived blockers. Meridian's new K-Block and Mouse-Free IgG overcome the obstacles associated with conventional animal-based blockers. These advanced blockers enhance assay specificity, reduce lot-to-lot variability, comply with sustainability considerations, and minimize contamination risks from animal-derived components. Preliminary testing in ELISA-based assays has revealed a strong performance of K-Block and Mouse-FREE IgG compared to other commercial animal-derived blockers.

The introduction of these products is in line with Meridian's objective to pioneer sustainable and innovative raw materials for diagnostic assay manufacturers. By adopting these animal-free products, manufacturers can contribute to reducing their environmental footprint by optimizing energy and resource consumption and maintaining compliance with emerging regulatory standards. Meridian continues to champion environmental responsibility within the industry and is showcasing the two new animal-free immunoassay interference blockers, K-Block, and Mouse-Free IgG, at AACC 2023.

“At Meridian, we are deeply committed to supporting our customers who are seeking non-animal-derived raw materials in diagnostic assays,” said Lourdes Weltzien, Ph.D., President - Life Science, Meridian Bioscience. “Our novel 100% animal-free blockers deliver on this commitment while avoiding the need to consume millions of mice each year in the process. This innovative method not only allows us to scale up quickly but also delivers results that are equivalent or even superior in quality. With this new product line, we reaffirm our dedication to environmental sustainability and social responsibility, ensuring a more ethical and responsible approach in our operations as well as our customers.”

Related Links:
Meridian Bioscience Inc. 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Chlamydia Pneumoniae Test
Chlamydia Pneumoniae (CP) Real Time PCR Kit
New
Amoebiasis Test
ELI.H.A Amoeba
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.